This site is intended for healthcare professionals
News

Health Canada approves Descovy for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection.- Gilead Sciences

Read time: 1 mins
Last updated:24th Sep 2021
Published:9th Apr 2020
Gilead Sciences' Canada has filed a supplemental marketing application with Health Canada seeking approval for Descovy (emtricitabine 200 mg and tenofovir alafenamide 25 mg tablets) for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection among individuals who are HIV-negative and at risk for HIV. Descovy was approved in Canada in 2016 for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 35 kg (in combination with other antiretrovirals).
Condition: HIV Prevention
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Related news and insights